Skip to main content
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Approval of TARDOC outpatient tariff structure postponed in Switzerland

22 Jul 2021

On June 30, 2021, the Swiss Federal Council announced that the TARDOC outpatient tariff structure, presented by the association of insurers curafutura and the Swiss Medical Association (FMH), cannot be approved at this point. The Federal Council found the TARDOC tariff structure to have many drawbacks and that it would not guarantee cost neutrality. More specifically, the requirements are met only partially, in particular with regard to equity and cost-effectiveness. Also, the Federal Council notes that the TARDOC tariff structure was not supported (signed) by the Swiss Hospital Association (H+) and the association of insurers (santésuisse), which are the key stakeholders in the Swiss healthcare system.

In November 2020, the Federal Office of Public Health (FOPH) submitted a detailed audit report to the TARDOC founders. The Federal Council concluded that no essential recommendations of the FOPH were implemented in the revised version of TARDOC.

The Federal Council did not reject the TARDOC tariff structure; It invites all stakeholders to conduct an in-depth review of the FOPH's recommendations and to jointly revise the TARDOC tariff structure.

Curafutura released an announcement, in which they state that they will continue working on the TARDOC tariff structure and will try to implement as many changes as possible, according to the FOPH recommendations, until the end of 2021, and will invite H+ and santésuisse to collaborate. This means that the TARDOC tariff structure is not likely to be implemented before January 2023.

See more details here and here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news).

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks). First EU issues of both newsletters are available for download free-of-charge.